Want to see JP:2927 full AI Analyst Report?
AFC-HD AMS Life Science Co., Ltd. (2927) AI Stock Analysis
Top Page
AFC-HD AMS Life Science Co., Ltd.
(TSE/TYO:2927)
Overall score is driven primarily by financial performance: steady revenue growth and positive profitability are offset by persistently weak free cash flow and only moderate balance-sheet strength. Technical indicators add near-term caution due to weak momentum, while valuation (low P/E and high dividend yield) provides a meaningful supportive offset.
AFC-HD AMS Life Science Co., Ltd. (2927) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 12.42B
- Dividend Yield
- 4.69%
- Average Volume (3M)
- 26.10K
- Price to Earnings (P/E)
- 10.3
- Beta (1Y)
- 0.28
- Revenue Growth
- 5.11%
- EPS Growth
- -19.41%
- Country
- Japan
- Employees
- 1,008
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
AFC-HD AMS Life Science Co., Ltd. Business Overview & Revenue Model
Company Description
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and cosmetics. The company operates through five segments: Healthcare, Pharmaceutical, Department Store, Food and Beverage, and Other Business. The Healt...
How the Company Makes Money
The company primarily makes money by selling health-related products (e.g., supplements and other wellness products) through its commercial channels. Revenue is generated from product sales, which may include (1) branded product sales to consumers an...
AFC-HD AMS Life Science Co., Ltd. Financial Statement Overview
Summary
Mixed fundamentals. Income statement is decent (62) with steady revenue growth and positive operating profitability, but margins have compressed. Balance sheet is moderate (55) with meaningful leverage despite slight improvement. Cash flow is the key weakness (34): operating cash flow is modest versus debt and free cash flow has been negative in 4 of the last 5 years, limiting financial flexibility.
Income Statement
62PositiveBalance Sheet
55NeutralCash Flow
34Negative| Breakdown | TTM | Aug 2026 | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.32B | 34.32B | 32.66B | 30.19B | 25.58B | 23.00B |
| Gross Profit | 11.65B | 11.65B | 10.97B | 10.49B | 9.32B | 8.58B |
| EBITDA | 3.98B | 3.92B | 3.80B | 3.10B | 2.59B | 2.30B |
| Net Income | 1.20B | 1.20B | 1.45B | 1.25B | 1.10B | 735.35M |
Balance Sheet | ||||||
| Total Assets | 49.05B | 49.05B | 48.73B | 47.03B | 41.07B | 37.35B |
| Cash, Cash Equivalents and Short-Term Investments | 9.76B | 9.76B | 11.30B | 12.17B | 11.18B | 10.38B |
| Total Debt | 23.41B | 23.41B | 24.14B | 23.40B | 19.59B | 17.24B |
| Total Liabilities | 32.61B | 32.61B | 33.53B | 33.07B | 27.91B | 24.90B |
| Stockholders Equity | 16.21B | 16.21B | 15.08B | 13.93B | 13.11B | 12.44B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -726.43M | -1.75B | -1.87B | -1.07B | 534.45M |
| Operating Cash Flow | 0 | 1.68B | 1.79B | 1.54B | 865.28M | 1.49B |
| Investing Cash Flow | 0 | -2.85B | -3.33B | -2.76B | -1.95B | -1.08B |
| Financing Cash Flow | 0 | -616.99M | 666.75M | 2.23B | 1.88B | 1.16B |
AFC-HD AMS Life Science Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2927, the sentiment is Neutral. The current price of 853.00 is above the 20-day moving average (MA) of 852.55, below the 50-day MA of 858.91, and above the 200-day MA of 848.75, indicating a neutral trend. The MACD of 0.64 indicates Negative momentum. The RSI at 48.63 is Neutral, neither overbought nor oversold. The STOCH value of 9.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2927.
AFC-HD AMS Life Science Co., Ltd. Peers Comparison
Overall Rating
JP:452681Outperform
JP:137578Outperform
JP:200274.15Outperform
JP:313960Neutral
JP:293658Neutral- JP:292756Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4526 | 81Outperform | JPY 78.33B | 14.24 | ― | 3.20% | 3.11% | -17.81% |
| JP:1375 | 78Outperform | JPY 45.02B | 13.68 | ― | 2.13% | 4.27% | 243.52% |
| JP:2002 | 74Outperform | JPY 611.79B | 15.68 | ― | 2.77% | 2.60% | 69.40% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| JP:3139 | 60Neutral | JPY 34.69B | 9.80 | ― | 4.27% | 5.61% | -15.32% |
| JP:2936 | 58Neutral | JPY 13.35B | 240.38 | ― | ― | 3.21% | -90.33% |
| JP:2927 | 56Neutral | JPY 12.09B | 10.28 | ― | 4.69% | 5.11% | -19.41% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2927 | AFC-HD AMS Life Science Co., Ltd. | 853.00 | 39.37 | 4.84% | |
| JP:1375 | YUKIGUNI MAITAKE CO., LTD. | 1128.00 | 121.48 | 12.07% | |
| JP:2002 | Nisshin Seifun Group Inc. | 2236.00 | 546.41 | 32.34% | |
| JP:2936 | BASE FOOD Inc. | 250.00 | -90.00 | -26.47% | |
| JP:3139 | Lacto Japan Co., Ltd. | 3465.00 | 152.16 | 4.59% | |
| JP:4526 | Riken Vitamin Co., Ltd. | 3435.00 | 735.11 | 27.23% |
AFC-HD AMS Life Science Co., Ltd. Corporate Events
AFC-HD AMS Life Science Posts Higher Sales but Lower Profit for FY2026
AFC-HD AMS Life Science reported consolidated net sales of ¥34,324 million for the fiscal year ended August 31, 2026, a 5.1% increase from the previous year, supported by steady operating performance that lifted operating profit slightly to ...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026